Overview First Published Online October 1 , 2014 DOI : 10 . 1634 / theoncologist . 2014 - 0223 Title : S - 1 as Monotherapy or in Combination With Leucovorin as Second - Line Treatment in Gemcitabine - Refractory
نویسندگان
چکیده
Authors: Feijiao Ge, Nong Xu, Yuxian Bai, Yi Ba, Yanqiao Zhang, Fei Li, Huayan Xu, Ru Jia, Yan Wang, Li Lin, Jianming Xu Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, People’s Republic of China; The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, People’s Republic of China; The Third Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China; Cancer Hospital of Tianjin Medical University, Tianjin, People’s Republic of China; Xuanwu Hospital of Capital Medical University, Beijing, People’s Republic of China
منابع مشابه
S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer
BACKGROUND Pancreatic cancer (PC) is one of the most lethal digestive system tumors. Most new cases are diagnosed based on metastasis or local aggression and are known as "advanced PC." Recently, studies investigating S-1 have indicated that it has a better clinical curative effect on PC. We conducted a meta-analysis to evaluate the efficacy and safety of S-1 monotherapy compared with S-1 combi...
متن کاملIs there a role for second line therapy in advanced pancreatic cancer?
FOLFIRINOX (5-FU, oxaliplatin and irinotecan) and gemcitabine based regimens are widely used for the first-line treatment for patients with advanced pancreatic adenocarcinoma. Nab-paclitaxel and gemcitabine has replaced the use of many single agent gemcitabine in these patients population. In patients who progress on the first line therapy use of either 5-FU, leucovorin and oxaliplatin (FOLFOX)...
متن کاملTreatment of metastatic pancreatic adenocarcinoma: a review.
Gemcitabine monotherapy has been the standard of care for patients with metastatic pancreatic cancer for several decades. Despite recent advances in various chemotherapeutic regimens and in the development of targeted therapies, metastatic pancreatic cancer remains highly resistant to chemotherapy. Previous studies of several combination regimens showed minimal or no significant change in overa...
متن کاملCost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.
BACKGROUND The accord 11/0402 trial demonstrated that folfirinox (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) is significantly more efficacious than gemcitabine monotherapy in the first-line treatment of metastatic pancreatic cancer (mpc). The present study assessed the cost-effectiveness of first-line folfirinox compared with first-line gemcitabine for public payers in Canada. METHO...
متن کاملPancreatic Cancer: Progress in Systemic Therapy.
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths in the Western world. Due to lack of specific symptoms and no accessible precursor lesions, primary diagnosis is commonly delayed, resulting in the identification of only 15-20% of patients with potentially curable disease. The major limiting factor is an already locally advanced or metastatic disease...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2014